Pavlo Kot

Humacyte Phase 3 V012 trial results of ATEV in hemodialysis access to be presented

Humacyte Phase 3 V012 trial results of ATEV in hemodialysis access to be presented
Humacyte to present ATEV data

Humacyte announced that results from its Phase 3 V012 trial of ATEV in women requiring hemodialysis access have been accepted for presentation in a late-breaking oral session at ASN Kidney Week 2026.

This event is a leading forum for kidney health professionals, suggesting increased visibility for Humacyte's clinical research and its potential impact in the field of kidney health. The acceptance underscores the company's ongoing progress with ATEV as a potential therapeutic option for patients undergoing hemodialysis.

Humacyte recently completed its first commercial Symvess procedure in Florida at Sacred Heart Emerald Coast, expanding the product's reach into new clinical settings. Earlier this year, the company received FDA authorization to extend Symvess shelf life to 36 months to support hospital storage and preparedness. These developments reflect Humacyte's continued activity in vascular access technologies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.